Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types.
PPARgamma is a therapeutic target that has been exploited for treatment of type II diabetes mellitus (T2DM) with agonist drugs. Since PPARgamma is expressed by many hematopoietic, mesodermal and epithelial cancers, agonist drugs were tested and shown to have both preclinical and clinical anticancer activities. While preclinical activity has been observed in many cancer types, clinical activity has been observed only in pilot and phase II trials in liposarcoma and prostate cancer. Most studies address agonist compounds, with substantially fewer reports on anticancer effects of PPARgamma antagonists. In cancer model systems, some effects of PPARgamma agonists were not inhibited by PPARgamma antagonists, suggesting noncanonical or PPARgamma-independent mechanisms. In addition, PPARgamma antagonists, such as T0070907 and GW9662, have exhibited antiproliferative effects on a broad range of hematopoietic and epithelial cell lines, usually with greater potency than agonists. Also, additive antiproliferative effects of combinations of agonist plus antagonist drugs were observed. Finally, there are preclinical in vivo data showing that antagonist compounds can be administered safely, with favorable metabolic effects as well as antitumor effects. Since PPARgamma antagonists represent a new drug class that holds promise as a broadly applicable therapeutic approach for cancer treatment, it is the subject of this review.
Burton
Jack D
JD
Coney Island Hospital, 2601 Ocean Parkway, Brooklyn, NY 11235, USA.
Goldenberg
David M
DM
Blumenthal
Rosalyn D
RD
Int J Cancer. 2007 Feb 1;120(3):702-13
17096328
J Biol Chem. 1995 Jun 2;270(22):12953-6
7768881
Anticancer Drugs. 2007 Jun;18(5):525-34
17414621
Cancer Sci. 2006 Sep;97(9):854-60
16805824
Cancer Res. 1999 Jan 15;59(2):336-41
9927043
Mol Endocrinol. 2002 Nov;16(11):2628-44
12403851
Mol Cell. 1998 Feb;1(3):465-70
9660931
Biochem J. 2002 Mar 15;362(Pt 3):573-8
11879183
J Biol Chem. 1997 Aug 8;272(32):20230-5
9242701
Anticancer Res. 2004 Sep-Oct;24(5A):2765-71
15517883
Clin Cancer Res. 2004 Oct 1;10(19):6606-11
15475450
Cancer Res. 2001 Aug 15;61(16):6213-8
11507074
Crit Care Med. 2006 Apr;34(4):1131-8
16484917
J Biol Chem. 1997 Oct 3;272(40):25252-9
9312141
Immunity. 2004 Feb;20(2):205-18
14975242
Br J Pharmacol. 2000 Oct;131(4):651-4
11030710
Clin Cancer Res. 2001 Jan;7(1):98-104
11205925
Br J Pharmacol. 2004 Dec;143(8):933-7
15533890
J Immunol. 2003 Oct 1;171(7):3863-71
14500688
Cancer Res. 2005 Mar 15;65(6):2251-9
15781638
Nature. 2005 Sep 29;437(7059):759-63
16127449
Cancer Res. 2001 Jul 1;61(13):5307-10
11431375
Crit Care Med. 2005 Oct;33(10):2309-16
16215386
Cancer Res. 1998 Aug 1;58(15):3344-52
9699665
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6
10097144
Clin Cancer Res. 2005 Jun 1;11(11):4012-21
15930335
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):7939-44
9653119
J Biol Chem. 2000 Oct 27;275(43):33201-4
10944516
Cancer Res. 2000 Aug 1;60(15):4262-9
10945640
Blood. 2004 Dec 1;104(12):3705-11
15297317
Blood. 2001 Jan 15;97(2):483-9
11154226
Biochem Biophys Res Commun. 1993 Oct 29;196(2):671-7
8240342
J Biol Chem. 1993 Dec 25;268(36):26817-20
8262913
J Biol Chem. 2000 Jan 21;275(3):1873-7
10636887
Genes Dev. 1998 Nov 1;12(21):3357-68
9808623
Carcinogenesis. 1998 Jan;19(1):49-53
9472692
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5
10984506
Mol Cell Biol. 1997 Apr;17(4):2166-76
9121466
Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):237-41
8990192